LORD, ABBETT & CO. LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
LORD, ABBETT & CO. LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2022$19,373,000
-15.0%
324,724
+3.5%
0.07%
+11.5%
Q1 2022$22,784,000
-13.6%
313,744
+0.0%
0.06%
+1.7%
Q4 2021$26,378,000
-32.0%
313,681
-27.0%
0.06%
-35.5%
Q3 2021$38,773,000
+11.5%
429,906
+17.8%
0.09%
+10.7%
Q2 2021$34,784,000
-19.1%
364,809
-3.4%
0.08%
-23.6%
Q1 2021$43,019,000
+106.1%
377,826
+38.2%
0.11%
+89.7%
Q3 2018$20,877,000
+87.2%
273,479
+74.0%
0.06%
+70.6%
Q3 2016$11,150,000
-32.4%
157,176
-53.4%
0.03%
-34.6%
Q2 2016$16,490,000
+67.1%
337,153
+116.3%
0.05%
+67.7%
Q1 2016$9,869,000
-68.5%
155,883
-44.3%
0.03%
-67.0%
Q4 2015$31,378,000
+40.7%
279,713
+20.8%
0.09%
+40.3%
Q3 2015$22,303,000
-70.1%
231,580
-68.2%
0.07%
-65.8%
Q2 2015$74,505,000
+91.0%
727,659
+15.8%
0.20%
+98.0%
Q1 2015$39,013,000
+108.0%
628,332
+47.0%
0.10%
+106.2%
Q4 2014$18,755,000
-42.6%
427,416
-26.0%
0.05%
-41.5%
Q3 2014$32,694,000
+57.1%
577,631
+24.6%
0.08%
+241.7%
Q2 2014$20,816,000
+686.4%
463,732
+756.5%
0.02%
+300.0%
Q1 2014$2,647,00054,1440.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2021
NameSharesValueWeighting ↓
Iguana Healthcare Management, LLC 75,000$5,084,0002.52%
COLUMBIA WANGER ASSET MANAGEMENT LLC 1,237,825$83,900,0001.18%
CAPITAL INTERNATIONAL LTD /CA/ 206,718$14,011,0000.91%
Cormorant Asset Management, LP 75,000$5,084,0000.74%
Capital International Sarl 107,450$7,283,0000.63%
Rock Springs Capital Management LP 159,750$10,828,0000.62%
Opus Point Partners Management, LLC 12,201$827,0000.61%
Hood River Capital Management LLC 109,629$7,431,0000.56%
Aureus Asset Management, LLC 50,740$2,927,0000.51%
ROCKEFELLER FINANCIAL SERVICES INC 374,663$25,395,0000.51%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders